Breye Therapeutics commences oral dosing of danegaptide in patients with diabetic retinopathy

Breye Therapeutics (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, has announced the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular edema (DME).

Breye is developing novel, oral ophthalmology drugs to address the need for more effective and less burdensome therapies for millions of patients suffering with deteriorating vision due to Diabetic Retinopathy (DR) or Age-Related Macular Degeneration (AMD). While there has been successful development of intravitreally administered products for patients with late-stage disease, treatment options are currently limited for patients in the early or moderate stages.

As an oral therapy, danegaptide targets the core pathological events in DR, including cell-cell uncoupling, apoptotic vascular cell death and vascular leakage, at earlier stages of disease progression. With safety data derived from over 500 clinical trial participants, robust toxicology data, and strong non-clinical in vitro and in vivo efficacy results, there is strong support for danegaptide's potential to address the clinical core ocular pathologies of vascular leakage and capillary breakdown. The positive effects of treating these pathologies have been clinically validated.

The study's design is a multicenter, open-label, dose-escalating Phase 1b/2a study to assess the safety, tolerability, pharmacokinetics (PK), and early signs of biological activity following oral administration of danegaptide in participants diagnosed with DME.

Ulrik Mouritzen, CEO, Breye Therapeutics: "The launch of the Phase 1b/2a clinical trial for danegaptide represents a significant milestone towards realising our mission of developing more effective, globally accessible orally administered treatment solutions for patients at risk of vision loss and blindness. The burden on patients with diabetic retinopathy is significant and those who experience vision loss and blindness face threats to their physical and mental health and overall quality of life. At Breye, we are committed to help treat the disease earlier by offering effective oral therapies, to patients who currently have limited or no treatment options."

www.breye.com